After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...

From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged ...

In a year that saw advisory committees placed under a particularly bright microscope at the FDA, the agency held fewer ...

Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and ...

While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set ...

The US dramatically altered its recommendations for a series of vaccines, which drive billion-dollar earnings for giants like ...

In this deep dive, BioSpace looks at recent breakthroughs and three decades of progress in treating Huntington's disease.

Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently ...

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...

Industry leaders are focused on the resilience of key starting material supply and the knock-on effects of automation in the ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

After getting the crucial first-mover advantage with an FDA approval for a weight loss pill, Novo Nordisk looks to win the ...